Effect of Slow Release Hydrocortisone on Fed & Fasting Volunteers; Immediate Release on Fasting Only

• ClinicalTrials.gov Identifier: NCT02408068
• Recruitment Status: Completed
• First Posted: April 3, 2015
• Results First Posted: December 15, 2017
• Last Update Posted: December 15, 2017
• Sponsor: Diurnal Limited
• Collaborator: Simbec Research
• Information provided by (Responsible Party): Diurnal Limited

Study Description

Brief Summary:

The purpose of the study is to find out whether food has an effect on the way the body deals with modified release hydrocortisone, and to compare with the pharmacokinetics of immediate release hydrocortisone (fasted). This information will be used to help doctors with dosing in clinical practice.

Condition or disease	Intervention/treatment	Phase
Healthy	Drug: Dexamethasone; Drug: Chronocort: fasted; Drug: Immediate release hydrocortisone: fasted; Drug: Chronocort: fed	Phase 1

Detailed Description:

This is a phase I study in healthy male volunteers, who will be given dexamethasone to suppress their natural cortisol production. 18 will be consented for the study. They will have had a history and a physical examination, blood tests for routine safety, hepatitis C and HIV, drug abuse and ECGs. Following the results of these tests and the inclusion/exclusion criteria for the study, they will be admitted to the phase I unit on the first afternoon (Day -1). They will be given dexamethasone at 22.00hrs that evening, and remain in the unit until the end of the period. Further dexamethasone doses will be given at 06:00, 12:00, and 18:00 hours on Day 1 (plus at 22:00 hours in patients given the modified release study drug). Each volunteer will be admitted for 3 periods of approximately 1.5 days, with a washout of 7 days between periods, and they will be randomised to either fast and take a single 20mg dose of immediate release hydrocortisone, to fast and take a single 20mg dose of the study medication, (a modified release hydrocortisone), or to the "fed" group, where they take a single dose of 20mg study medication, and have a highly calorific standardised breakfast. The volunteers will have cannulae to enable one pre-dose blood sample to be taken followed by 24 hour PK sampling (modified release) and 12 hour PK sampling for the immediate release period. After these samples have been taken the volunteers will be able to leave the unit. There will be another assessment 3 to 5 days after study period 3 with further blood tests, assessment of any adverse events etc.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 18 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: None (Open Label)
• Primary Purpose: Basic Science
• Official Title: Open Label Randomised 3 Period Crossover Study to Evaluate Bioavailability of Modified Release Hydrocortisone (HC) Under Fasting & Fed Conditions & Immediate Release HC Tablets Under Fasting Conditions in Dexamethasone-suppressed Subjects
• Study Start Date: January 2015
• Actual Primary Completion Date: March 2015
• Actual Study Completion Date: March 2015

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Chronocort : fed; Volunteers will be admitted, take dexamethasone at 22.00hrs, fast overnight, and receive a high fat, high calorie breakfast on the morning of Day 1. Thirty minutes after the start of the breakfast they will receive 20mg of modified release hydrocortisone with 200 millilitres of water, and no further food for 4 hours, water will be allowed from 1 hour after the food. Further dexamethasone doses will be given at 06:00, 12:00, 18:00 and 22:00 hours on Day 1. One baseline pharmacokinetics (PK) sample will be taken starting prior to the dose and then over 24 hours (29 samples).	Drug: Dexamethasone; Dexamethasone used to suppress endogenous cortisol secretion; Drug: Chronocort: fed; single dose of 20mg modified release hydrocortisone in the presence of food; Other Name: modified release hydrocortisone
Active Comparator: Immediate release hydrocortisone: fasted; Volunteers will be admitted, take dexamethasone at 22.00hrs, fast overnight, and take 20mg immediate release hydrocortisone with 200 millilitres of water on the morning of Day 1. Water will be allowed 1hr after the study drug, but no food for at least 4hrs post dose. Further dexamethasone doses will be given at 06:00, 12:00 and 18:00 hours on Day 1. One baseline pharmacokinetics (PK) sample will be taken prior to the dose, and then afterwards for over a 12 hour period (16 samples)	Drug: Dexamethasone; Dexamethasone used to suppress endogenous cortisol secretion; Drug: Immediate release hydrocortisone: fasted; single dose of 20mg immediate release hydrocortisone in the absence of food; Other Name: Hydrocortisone
Active Comparator: Chronocort: fasted; Volunteers will be admitted, take dexamethasone at 22.00hrs, fast overnight, and take 20mg modified release hydrocortisone with 200millilitres of water on the morning of Day 1. Water will be allowed 1hr after the dose, but no food for at least 4hrs post dose. Further dexamethasone doses will be given at 06:00, 12:00, 18:00 and 22:00 hours on Day 1. One baseline pharmacokinetics (PK) sample will be taken prior to the dose, and then afterwards for over a 12 hour period (16 samples)	Drug: Dexamethasone; Dexamethasone used to suppress endogenous cortisol secretion; Drug: Chronocort: fasted; single dose of 20mg modified release hydrocortisone in the absence of food; Other Name: modified release hydrocortisone

Outcome Measures

Primary Outcome Measures :

1. Chronocort Cmax [ Time Frame: 24 hours ]
   Comparison of fed and fasted Chronocort Cmax for serum cortisol.
2. Comparison of Fed and Fasted Chronocort AUC0-t [ Time Frame: 24 hours (at 0h, then 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, 6h, 6.5h, 7h, 7.5h, 8h, 9h, 10h, 11h, 12h, 13h, 14h, 15h, 16h, 18h, 20h, 22h and 24h post-dose.) ]

   Area under the curve from 0 to 24 hours for serum cortisol. Please note that the AUC0-t will be presented as a single figure (geometric mean) to represent exposure over time.

   N.B., the sampling points for Hydrocortisone are as follows: 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 8h, 10h and 12h post-dose. However, the results for Hydrocortisone will not be incorporated into the analysis for this outcome measure.

3. Comparison of Fed and Fasted Chronocort Tmax [ Time Frame: 24 hours ]
   Comparison of Fed and Fasted Chronocort based on the time to achive the maximum concentration of serum cortisol
4. Bioavailability of Chronocort® vs Hydrocortisone Tablets - Cmax [ Time Frame: 24 hours ]
   Evaluation of the relative bioavailability of Chronocort® and immediate release hydrocortisone at a single dose of 20 mg in the fasted state by Cmax
5. Bioavailability of Chronocort® vs Hydrocortisone Tablets - Fasted Using AUC0-t [ Time Frame: 24 hours ]
   To evaluate the relative bioavailability of Chronocort® and immediate release hydrocortisone at a single dose of 20 mg in the fasted state using area under the curve
6. Bioavailability of Chronocort® vs Hydrocortisone Tablets - Fasted Using Tmax. [ Time Frame: 24 hours ]
   To evaluate the relative bioavailability of Chronocort® and immediate release hydrocortisone at a single dose of 20 mg in the fasted state using Tmax.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 60 Years (Adult)
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Healthy male volunteers between 18 and 60 years of age, inclusive (at screening)
• A body mass index of 21-28 (inclusive).
• No clinically significant abnormal serum biochemistry, haematology and urine examination values
• A negative urinary drugs of abuse screen. A positive alcohol test may be repeated at the discretion of the investigator.
• Negative HIV and Hepatitis b & C results
• No clinically significant abnormalities in 12-lead ECG
• No clinically significant deviation outside the normal ranges for blood pressure and pulse measurements

• Subjects (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) and sexual partners must use effective contraception methods during the trial and for 3 months after the last dose, for example:

  • Oral contraceptive + condom
  • Intra-uterine device + condom
  • Diaphragm with spermicide + condom
• Subjects must be available to complete the study
• Subjects must provide written informed consent to participate in the study

Exclusion Criteria:

• A clinically significant history of gastrointestinal disorder likely to influence drug absorption
• Receipt of regular medication (including high dose vitamins, dietary supplements or herbal remedies)
• Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction Receipt of any vaccination within the previous one month
• Presence of clinically significant infections (systemic fungal and viral infections, acute bacterial infections)
• Current of previous history of tuberculosis
• A clinically significant history of previous allergy/sensitivity to hydrocortisone and/or dexamethasone
• A clinically significant history of family history of psychiatric disorders/illnesses
• A clinically significant history of drug or alcohol abuse
• Inability to communicate well with the investigator (ie language problem, poor mental development or impaired cerebral function)
• Participation in a New Chemical entity clinical study within the previous four months or a marketed drug clinical study within the previous three months
• Subjects who have consumed more than two units of alcohol pre day within seven days prior to the first dose or have consumed any alcohol within the 48hr period prior to the first dose
• Donation of greater than or equal to 450ml blood within the previous three months
• Subjects who smoke or ex-smokers who have smoked within six months prior to first dose
• Subjects who work shifts (ie regularly alternate between days, afternoons and nights)

Contacts and Locations

No Contacts or Locations Provided

More Information

• Responsible Party: Diurnal Limited
• ClinicalTrials.gov Identifier: NCT02408068
• Other Study ID Numbers: DIUR-004
• First Posted: April 3, 2015
• Results First Posted: December 15, 2017
• Last Update Posted: December 15, 2017
• Last Verified: May 2017

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Keywords provided by Diurnal Limited:

subjects

Additional relevant MeSH terms:

Dexamethasone; Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate; Hydrocortisone hemisuccinate; Anti-Inflammatory Agents; Antiemetics; Autonomic Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Gastrointestinal Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Agents